AI and ma­chine learn­ing: FDA spells out specifics from drug dis­cov­ery to man­u­fac­tur­ing

From drug tar­get iden­ti­fi­ca­tion and ear­ly dis­cov­ery work to post­mar­ket sur­veil­lance and ad­vanced man­u­fac­tur­ing, the FDA on Wednes­day out­lined its key rec­om­men­da­tions on how to use ar­ti­fi­cial in­tel­li­gence and ma­chine learn­ing, two new and key com­po­nents to drug de­vel­op­ment that the agency is try­ing to bet­ter un­der­stand.

The 31-page dis­cus­sion pa­per and web­site note that the FDA has seen a sig­nif­i­cant in­crease in the num­ber of drug and bi­o­log­ic ap­pli­ca­tion sub­mis­sions us­ing AI/ML com­po­nents over the past few years, with more than 100 sub­mis­sions re­port­ed in 2021.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA